2015 American Transplant Congress
Alemtuzumab Induction Is Protective Against Acute Rejection in Kidney Recipients With Subtherapeutic Tacrolimus Concentrations
Transplant Surgery, University of North Carolina Hospitals, Chapel Hill, NC.
Purpose: To determine the effect of attaining early therapeutic tacrolimus (TAC) trough concentrations on biopsy-proven acute rejection (BPAR) within 12 months post-transplantation in adult kidney…2015 American Transplant Congress
Induction of a Costimulation-Susceptible Repertoire: A Case for Depletional Prior to Belatacept
1Surgery, Duke University, Durham, NC; 2Transplant Center, Emory University, Atlanta, GA.
Belatacept offers highly specific costimulation blockade to prevent recipient alloimmune responses with reduced toxicity. However, when applied with nondepletional induction therapy belatacept-based regimens have higher…2015 American Transplant Congress
Effect of Induction in Renal Transplant Recipients Aged 70 and Over
Transplantation, Montefiore Medical Center, Bronx, NY.
While there is a significant survival advantage to transplanting patients 70 years of age and older versus staying on dialysis, it is unclear whether sensitized…2015 American Transplant Congress
Preliminary Results of a Novel Induction Regimen Using Anti-Thymocyte Globulin (Rabbit) (rATG) Plus Basiliximab in a Pediatric Patient Population Undergoing Kidney Transplantation
Purpose: We report the outcomes from single center experience with the novel induction regimen using rATG (3 mg/kg) in divided doses given on operative day…2015 American Transplant Congress
Alemtuzumab Induction Is Associated With Higher Risk of Polyomavirrus Associated Nephropathy (PVAN) in Kidney Transplant Recipients
1Transplant, Mayo Clinic, Jacksonville, FL; 2Pharmacy, Mayo Clinic, Jacksonville, FL.
Incidence of PVAN on protocol kidney biopsies with alemtuzumab induction is unknown.Methods:The 1-year risk of PVAN was retrospectively compared between 200 consecutive primary kidney recipients…2015 American Transplant Congress
Delayed Graft Function in Patients Receiving Alemtuzumab Induction Therapy
1The University of Toledo Medical Center, Toledo, OH; 2The Alliance for Paired Donation, Maumee, OH.
Alemtuzumab (Campath 1-H) is a humanized monoclonal antibody directed at the CD52 glycoprotein that is becoming more prevalent as a choice for induction. Delayed graft…2015 American Transplant Congress
Evaluation of a Three-Dose Basiliximab Induction Immunosuppression Regimen in Adult Heart Transplant Recipients
University of Virginia Health System, Charlottesville, VA.
Background: Calcineurin inhibitors (CNI) are essential agents in most orthotopic heart transplantation (OHT) anti-rejection regimens. However, nephrotoxicity limits their use in the immediate post-OHT period,…2015 American Transplant Congress
Blood Gene Expression Profiling in a Randomized Controlled Trial of rATG Vs. IL2RA Induction Reveals the Differences in Immune Impact and Mechanisms
1MUSC, Charleston, SC; 2Scripps Research Institute, La Jolla, CA.
We performed global gene expression profiling using microarrays on samples from a prospective, RCT designed to study the safety & efficacy of induction with antithymocyte…2015 American Transplant Congress
Single Center Experience With the Use of an Abbreviated Anti-Thymocyte Globulin and Basiliximab Combination Protocol in Renal Transplantation
Purpose: To report one year outcomes from single center experience with a novel induction regimen using anti-thymocyte globulin ( ATG)(rabbit)rATG (3 mg/kg) in divided doses…2015 American Transplant Congress
Alemtuzumab in Elderly Renal Transplant Recipients Is Not Associated With a Poor Outcome
Imperial College Renal and Transplant Centre, Hammersmith Hospital, London, United Kingdom.
The use and choice of induction immunosuppression in elderly kidney recipients remains unresolved. Alemtuzumab has been associated with a higher risk of death and graft…
- « Previous Page
- 1
- …
- 26
- 27
- 28
- 29
- 30
- 31
- Next Page »